Boardroom Alpha
8-K primary document
DMAA · Current Report (Form 8-K) · Filed April 8, 2026

Drugs Made In America Acquisition Corp8-K exhibit

ea028552701ex10-1.htm

Exhibit 10.1

 

LETTER OF INTENT

 

 

Proposed Business Combination

Power Analytics Global Corp (“PAGC”)

and

Drugs Made in America Acquisition Corp (“DMAA”)

Dated: April 7, 2026

 

SECTION 1 – PARTIES

 

Power Analytics Global Corp (“PAGC”), a Delaware corporation.

 

Drugs Made in America Acquisition Corp (“DMAA”), a Cayman Islands exempted company and publicly traded special purpose acquisition company listed on Nasdaq.

 

SECTION 2 – PROPOSED TRANSACTION STRUCTURE

 

The Parties intend to enter into a definitive business combination agreement (the “Business Combination Agreement”) pursuant to which PAGC shall combine with DMAA in a transaction intended to qualify as a de-SPAC transaction, resulting in PAGC becoming a publicly listed company.

 

The structure, including merger mechanics, equity consideration, and governance, shall be set forth in the Business Combination Agreement and related SEC filings, including a registration statement on Form S-4.

 

SECTION 3 – VALUATION AND CONSIDERATION

 

The transaction is expected to reflect an implied equity valuation of approximately $1,000,000,000 for PAGC, subject to customary adjustments based on due diligence, capital structure, net debt, working capital, and market conditions.

 

Final consideration, including share exchange ratios and potential earn-out provisions, shall be determined in the Business Combination Agreement.

 

SECTION 4 – TRUST ACCOUNT; NON-RECOURSE (S-4 ALIGNED)

 

DMAA maintains a trust account for the benefit of its public shareholders (the “Trust Account”).

 

In accordance with customary SPAC practice and to be reflected in the Business Combination Agreement and Form S-4, no party hereto shall have any right, title, interest, or claim of any kind in or to the Trust Account, except as expressly provided under applicable securities laws and the governing trust agreement.

 

The Trust Account shall not be used to satisfy any liabilities, obligations, or claims arising out of this Letter of Intent or the transactions contemplated hereby.

 

SECTION 5 – WAIVER OF CLAIMS AGAINST TRUST (MARKET STANDARD)

 

PAGC agrees that it shall not seek recourse against the Trust Account or any funds held therein for any reason, including any claim arising out of this Letter of Intent, the Business Combination Agreement, or the transactions contemplated thereby.

 

This provision is intended to be consistent with standard SPAC transaction documentation and shall be incorporated into definitive agreements.

 

 

SECTION 6 – EXTENSION AND SPONSOR SUPPORT

 

The Parties acknowledge that DMAA may require stockholder approval to extend its business combination deadline.

 

PAGC and/or its affiliates may support such extension through contributions or arrangements to be defined in definitive documentation.

 

SECTION 7 – MINIMUM CASH CONDITION

 

The Business Combination Agreement is expected to include a minimum cash condition, anticipated to be in the range of $25,000,000 to $50,000,000, subject to redemptions and final negotiation.

 

SECTION 8 – FINANCING AND PIPE

 

The Parties may pursue additional financing, including PIPE investments or other capital raising transactions, the terms of which shall be set forth in definitive agreements.

 

Such financing shall be independent of the Trust Account unless otherwise expressly agreed.

 

SECTION 9 – SEC PROCESS AND DISCLOSURE

 

The Parties intend to prepare and file with the SEC a registration statement on Form S-4 (or equivalent), including a proxy statement/prospectus, reflecting the terms of the Business Combination Agreement.

 

All financial statements, pro forma information, and disclosures shall be prepared in accordance with applicable SEC rules and PCAOB standards.

 

SECTION 10 – THIRD PARTY BENEFICIARY

 

The trustee of the Trust Account and its beneficiaries shall be entitled to rely on and enforce Sections 4 and 5.

 

SECTION 11 – CONFIDENTIALITY

 

The existence and terms of this Letter of Intent and all discussions shall remain confidential, except as required by law or SEC disclosure obligations.

 

SECTION 12 – NON-BINDING; TRANSITION TO DEFINITIVE AGREEMENTS

 

This Letter of Intent is non-binding except for Sections 4, 5, 10, and 11.

 

The Parties agree to negotiate in good faith to enter into a definitive Business Combination Agreement, which shall supersede this Letter of Intent in its entirety.

 

SIGNATURES

 

POWER ANALYTICS GLOBAL CORP

 

By: /s/ Keith Barksdale  
Name: Keith Barksdale  
Title: Chairman  

 

DRUGS MADE IN AMERICA ACQUISITION CORP

 

By: /s/ Roger Bendelac  
Name: Roger Bendelac  
Title: CEO  

 

 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer